scholarly journals (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer

2020 ◽  
Vol 13 (3) ◽  
pp. 39
Author(s):  
Irina Velikyan
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Nuclear Medicine ◽  
Personalized Medicine ◽  
Patient Management ◽  
Neuroendocrine Neoplasms ◽  
Medicine Development ◽  
Oncological Patients

The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine.

Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences

2017 ◽  
Vol 474 (17) ◽  
pp. 2903-2924 ◽  
Author(s):  
Matthias Dedobbeleer ◽  
Estelle Willems ◽  
Stephen Freeman ◽  
Arnaud Lombard ◽  
Nicolas Goffart ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Solid Tumors ◽  
Primary Cancer ◽  
Key Factors ◽  
Cellular Functions ◽  
The Central Nervous System ◽  
Differentiation And Proliferation ◽  
Shed Light

Phosphatases and cancer have been related for many years now, as these enzymes regulate key cellular functions, including cell survival, migration, differentiation and proliferation. Dysfunctions or mutations affecting these enzymes have been demonstrated to be key factors for oncogenesis. The aim of this review is to shed light on the role of four different phosphatases (PTEN, PP2A, CDC25 and DUSP1) in five different solid tumors (breast cancer, lung cancer, pancreatic cancer, prostate cancer and ovarian cancer), in order to better understand the most frequent and aggressive primary cancer of the central nervous system, glioblastoma.

scholarly journals The role of general nuclear medicine in breast cancer

2015 ◽  
Vol 62 (1) ◽  
pp. 54-65 ◽  
Author(s):  
Lacey R. Greene ◽  
Deborah Wilkinson
Keyword(s):  
Breast Cancer ◽  
Nuclear Medicine

scholarly journals Personalized Medicine in Screening for Malignant Disease: A Review of Methods and Applications

2013 ◽  
Vol 8 ◽  
pp. BMI.S11153 ◽  
Author(s):  
F. Schmalfuss ◽  
P.L. Kolominsky-Rabas
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Colorectal Cancer ◽  
Personalized Medicine ◽  
Literature Search ◽  
Malignant Disease ◽  
Decisive Role ◽  
Routine Clinical Practice ◽  
Cancer Breast ◽  
Potential Applications

Personalized medicine (PM) is currently a hot topic in the professional world. It is often called the medicine of the future and has already achieved resounding success in the area of targeted therapy. Nevertheless, integration of the concepts of PM into routine clinical practice is slow. This review is intended to give an overview of current and potential applications of PM in oncology. PM could soon play a decisive role, especially in screening. The relevance of PM in screening was examined in the case of four common cancers (colorectal cancer, lung cancer, breast cancer, and prostate cancer). A literature search was performed. This showed that biomarkers in particular play a crucial role in screening. In summary, it can be emphasized that there are already numerous known promising biomarkers in malignant disease. This results in several possibilities for individualizing and revolutionizing screening.

scholarly journals The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine

2013 ◽  
Vol 183 (4) ◽  
pp. 1075-1083 ◽  
Author(s):  
Francine B. De Abreu ◽  
Wendy A. Wells ◽  
Gregory J. Tsongalis
Keyword(s):  
Breast Cancer ◽  
Personalized Medicine ◽  
Molecular Diagnostics

scholarly journals Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms

2017 ◽  
Vol 24 (6) ◽  
pp. R223-R237 ◽  
Author(s):  
Maria Chiara Zatelli ◽  
Erika Maria Grossrubatscher ◽  
Elia Guadagno ◽  
Concetta Sciammarella ◽  
Antongiulio Faggiano ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Personalized Medicine ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Resource Utilization ◽  
Clinical Management ◽  
Prognostic Markers ◽  
Neuroendocrine Neoplasms

The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking advantage of the most modern techniques, in the perspective of personalized medicine and appropriate resource utilization. This review summarizes the available data on the possible role of circulating tumor cells and microRNAs as prognostic markers in NENs.

Sign in / Sign up

Export Citation Format

Share Document